Patient Leaflet Updated 10-Sep-2025 | Ferring Pharmaceuticals Ltd
Pentasa Sachet 1g, 2g and 4g prolonged release granules
PENTASA®
Sachet 1g prolonged release granules
Sachet 2g prolonged release granules
Sachet 4g prolonged release granules
Mesalazine
What is in this leaflet:
1. What Pentasa Sachet is and what it is used for
2. What you need to know before you take Pentasa Sachet
3. How to take Pentasa Sachet
4. Possible side effects
5. How to store Pentasa Sachet
6. Contents of the pack and other information
Pentasa Sachet is used for the treatment of mild to moderate attacks of ulcerative colitis and to help maintain freedom from further attacks.
Ulcerative colitis is an inflammatory bowel disease in which the lining of the intestine becomes inflamed and develops many tiny breaks in its surface (ulcers) which may bleed.
Pentasa Sachet contains granules that slowly release the active ingredient (mesalazine). This helps reduce the inflammation and the painful symptoms.
Talk to your doctor or pharmacist before taking Pentasa Sachet:
Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach in the toilet water. It concerns a chemical reaction between mesalazine and bleach and is harmless.
Serious skin reactions including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.
While you are on treatment with this medicine, your doctor will normally arrange blood and urine tests to check your kidney function especially at the beginning of treatment.
Tell your doctor or pharmacist if you are using, or have recently used, any other medicines - including medicines obtained without a prescription. This is especially important if you are taking any of the following:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is limited experience with the use of mesalazine during pregnancy and breast-feeding. Blood disorders have been reported in newborns of mothers being treated with this medicine. The newborn may develop allergic reactions after breast-feeding, e.g. diarrhoea. If the newborn develops diarrhoea, breast-feeding should be discontinued.
This medicine is not known to affect the ability to drive and/or use machines.
Always take Pentasa Sachet exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
Adults:
To treat an attack of colitis, your doctor will usually prescribe a dose of up to 4 g mesalazine a day to be taken either once a day or in divided doses. This may be taken as one Pentasa Sachet 4 g or two Pentasa Sachet 2g once daily. Pentasa Sachet 1g might also be used to provide the dose that is most suited to you.
To help maintain freedom from further attacks, your doctor will usually prescribe 2 g mesalazine a day administered as one Pentasa Sachet 2g or two Pentasa Sachet 1g once daily
Use in children and adolescents
Children 6 years of age and older:
The dose for children will be calculated by your doctor and depends on the child’s weight. It is generally recommended that half the adult dose is given to children up to 40 kg of body weight and the normal adult dose to children above 40 kg of body weight.
You should take the granules orally (by mouth), immediately after opening the sachet, as described below. Do not chew the granules.
1. Open the foil sachet
2. Empty the contents of the sachet onto the tongue and wash the granules down immediately with some water or orange juice ensuring that none remain in the mouth
OR
3. Mix the entire content of the sachet with yogurt. Intake immediately without chewing on the granules.
In the event of overdose, contact your doctor or nearest casualty department immediately.
If you have forgotten to take a dose, then take it as soon as you remember, and then take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
There have been very few reports of a severe allergic reaction (including severe skin erosions that may affect the skin as the protective barrier of the body). The allergic reaction might lead to swelling of the face and neck and/or difficulty in breathing or swallowing (Quincke´s oedema). If this happens contact your doctor or nearest casualty department immediately.
Stop using mesalazine and seek medical attention immediately if you notice any of the following symptoms:
reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, widespread rash, fever and enlarged lymph nodes. These serious skin rashes can be preceded by fever and flu-like symptoms.
The following common side effects may affect up to 1 in 10 people:
The following rare side effects may affect up to 1 in 1,000 people:
The following very rare side effects may affect up to 1 in 10,000 people:
Not known (frequency cannot be estimated from the available data)
There have been very few reports of benign intracranial hypertension (build up of fluid around the brain) in adolescents. Symptoms include headache, nausea, vomiting, and/or visual or hearing disturbances.
If you get any of the side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and foil sachet. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicnes you no longer use. These measures will help protect the environment.
The active substance is mesalazine
Each sachet contains mesalazine 1 g, 2 g or 4 g.
The other ingredients are ethylcellulose and povidone.
This medicine contains prolonged release granules. The granules are white-grey to pale white-brown.
This medicine is presented in aluminium foil sachets in packs of:
Sachet 1g: 50, 100 or 150
Sachet 2g: 10, 60 or 120
Sachet 4g: 20, 30, 50 or 100
Not all pack sizes may be marketed.
This leaflet was last revised in January 2025
Pentasa, Ferring and the FERRING logo are trademarks of Ferring B.V.
2009056572
Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
+44 (0)844 931 0051
http://www.ferring.co.uk
+44 (0)844 931 0050
0800 111 4125